GlassScriptPhysician profile
Jerry A Dancik
NPI 1366412066
$16,533.23
in general payments reported to CMS, 2019-2025
40 companies · $2,146 in 2025
The $2,146 reported for 2025 was more than what 90% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,670 · 2020: $1,765 · 2021: $1,255 · 2022: $1,455 · 2023: $1,364 · 2024: $1,878 · 2025: $2,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,020 · Education: $369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,019.60 |
| Education | $369.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $6,155.79 | 2019-2025 | Jynarque, Voyxact |
| Amgen INC. | $1,046.55 | 2019-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $877.55 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $856.50 | 2019-2025 | Farxiga, Evusheld |
| Alexion Pharmaceuticals, INC. | $694.40 | 2019-2025 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $635.84 | 2020-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $612.53 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $545.66 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $529.10 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Travere Therapeutics, INC. | $495.53 | 2019-2025 | Thiola |
| Mallinckrodt Enterprises LLC | $447.41 | 2019 | |
| Opko Pharmaceuticals, LLC | $402.82 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $377.16 | 2024-2025 | |
| Horizon Therapeutics Plc | $237.25 | 2020-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $232.09 | 2020-2025 | Benlysta, Arexvy |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Dancik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.